{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:38:56Z","timestamp":1761061136723,"version":"build-2065373602"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Incyte Pharmaceuticals"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016185","name":"Aimmune Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016185","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DBV Technologies"},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.iac.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T08:24:55Z","timestamp":1599639895000},"page":"575-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biologics for the Treatment of Food Allergies"],"prefix":"10.1016","volume":"40","author":[{"given":"Kanwaljit K.","family":"Brar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Lanser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Nowak-Wegrzyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jaci.2010.07.026","article-title":"National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006","volume":"126","author":"Liu","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib2","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1542\/peds.2011-0204","article-title":"The prevalence, severity, and distribution of childhood food allergy in the United States","volume":"128","author":"Gupta","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib3","doi-asserted-by":"crossref","first-page":"e20181235","DOI":"10.1542\/peds.2018-1235","article-title":"The public health impact of parent-reported childhood food allergies in the United States","volume":"142","author":"Gupta","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaip.2014.07.007","article-title":"Prevalence and characteristics of adult-onset food allergy","volume":"3","author":"Kamdar","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaip.2016.10.006","article-title":"Racial differences in food allergy phenotype and health care utilization among US children","volume":"5","author":"Mahdavinia","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2011.09.018","article-title":"Anaphylaxis in a New York City pediatric emergency department: triggers, treatments, and outcomes","volume":"129","author":"Huang","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib7","doi-asserted-by":"crossref","first-page":"e20153678","DOI":"10.1542\/peds.2015-3678","article-title":"Socioeconomic disparities in the economic impact of childhood food allergy","volume":"137","author":"Bilaver","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.iac.2020.06.002_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.anai.2013.12.007","article-title":"Temporal trends and racial\/ethnic disparity in self-reported pediatric food allergy in the United States","volume":"112","author":"Keet","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib9","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jaci.2010.03.029","article-title":"US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up","volume":"125","author":"Sicherer","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaci.2013.10.029","article-title":"Case fatality and population mortality associated with anaphylaxis in the United States","volume":"133","author":"Ma","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1398-9995.2012.02829.x","article-title":"Under notification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10","volume":"67","author":"Tanno","year":"2012","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.002_bib13","doi-asserted-by":"crossref","first-page":"17098","DOI":"10.1038\/nrdp.2017.98","article-title":"Food allergy","volume":"4","author":"Renz","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jaci.2008.04.032","article-title":"Epidemiologic risks for food allergy","volume":"121","author":"Lack","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib15","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jaci.2015.12.1322","article-title":"Enquiring About Tolerance (EAT) study: feasibility of an early allergenic food introduction regimen","volume":"137","author":"Perkin","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2020.06.002_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1414850","article-title":"Randomized trial of peanut consumption in infants at risk for peanut allergy","volume":"372","author":"Du Toit","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2016.10.010","article-title":"Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel","volume":"139","author":"Togias","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaip.2019.09.039","article-title":"Timing of introduction, sensitization, and allergy to highly allergenic foods at age 3 years in a general-population Canadian cohort","volume":"8","author":"Simons","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2020.06.002_bib19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2020.06.002_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib21","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jaci.2017.12.1008","article-title":"Advances in the approach to the patient with food allergy","volume":"141","author":"Scurlock","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2017.11.004","article-title":"Treatment for food allergy","volume":"141","author":"Burks","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A\u00a0phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cea.12862","article-title":"Individually dosed omalizumab: an effective treatment for severe peanut allergy","volume":"47","author":"Brandstrom","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib26","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A\u00a0pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.002_bib27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib28","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaci.2016.01.001","article-title":"Food allergen immunotherapy: current status and prospects for the future","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaci.2009.03.045","article-title":"Safety of a peanut oral immunotherapy protocol in children with peanut allergy","volume":"124","author":"Hofmann","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"21","key":"10.1016\/j.iac.2020.06.002_bib32","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jaci.2016.09.053","article-title":"Oral immunotherapy-induced gastrointestinal symptoms and peripheral blood eosinophil responses","volume":"139","author":"Goldberg","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaip.2016.11.010","article-title":"Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab","volume":"5","author":"Burk","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2020.06.002_bib35","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaci.2016.07.030","article-title":"Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy","volume":"139","author":"Virkud","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2S","key":"10.1016\/j.iac.2020.06.002_bib36","doi-asserted-by":"crossref","first-page":"AB104","DOI":"10.1016\/j.jaci.2013.12.387","article-title":"Omalizumab pretreatment does not protect against peanut oral immunotherapy-related adverse gastrointestinal events","volume":"133","author":"Le","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2S","key":"10.1016\/j.iac.2020.06.002_bib37","doi-asserted-by":"crossref","first-page":"AB28","DOI":"10.1016\/j.jaci.2011.12.765","article-title":"Peanut oral immunotherapy and omalizumab treatment for peanut allergy","volume":"129","author":"Henson","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.002_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/mi.2012.5","article-title":"Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab","volume":"5","author":"Bedoret","year":"2012","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaip.2018.09.015","article-title":"Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab","volume":"7","author":"Yee","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2020.06.002_bib40","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0002-8223(02)90351-2","article-title":"Food allergies in children affect nutrient intake and growth","volume":"102","author":"Christie","year":"2002","journal-title":"J\u00a0Am Diet Assoc"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib41","first-page":"630","article-title":"Kwashiorkor in the United States: fad diets, perceived and true milk allergy, and nutritional ignorance","volume":"137","author":"Liu","year":"2001","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib42","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2007.09.040","article-title":"The natural history of egg allergy","volume":"120","author":"Savage","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib43","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jaci.2007.08.023","article-title":"The natural history of IgE-mediated cow's milk allergy","volume":"120","author":"Skripak","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00281-012-0333-9","article-title":"Immunological mechanisms for desensitization and tolerance in food allergy","volume":"34","author":"Rachid","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/pai.12567","article-title":"Anti-IgE-assisted desensitization to egg and cow's milk in patients refractory to conventional oral immunotherapy","volume":"27","author":"Martorell-Calatayud","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"issue":"7","key":"10.1016\/j.iac.2020.06.002_bib46","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/pai.12259","article-title":"Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg","volume":"25","author":"Lafuente","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab","volume":"10","author":"Begin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.002_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A\u00a0phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"14","key":"10.1016\/j.iac.2020.06.002_bib50","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2020.06.002_bib51","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaci.2019.12.003","article-title":"Rapid desensitization of humanized mice with anti-human Fc epsilon RI alpha monoclonal antibodies","volume":"145","author":"Khodoun","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib52","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jaci.2013.02.043","article-title":"Rapid polyclonal desensitization with antibodies to IgE and Fc epsilon RI alpha","volume":"131","author":"Khodoun","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaip.2018.07.027","article-title":"Dupilumab for treatment of food allergy","volume":"7","author":"Rial","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib55","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"22","key":"10.1016\/j.iac.2020.06.002_bib56","doi-asserted-by":"crossref","first-page":"e131347","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.iac.2020.06.002_bib57","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib58","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2020.06.002_bib59","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2013.11.029","article-title":"Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice","volume":"18","author":"Yamaki","year":"2014","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.iac.2020.06.002_bib61","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12016-018-8694-z","article-title":"Enhancing the safety and efficacy of food allergy immunotherapy: a review of adjunctive therapies","volume":"55","author":"Virkud","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"515","key":"10.1016\/j.iac.2020.06.002_bib62","doi-asserted-by":"crossref","first-page":"eaax2945","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.iac.2020.06.002_bib63","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jaci.2017.12.987","article-title":"Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy [published correction appears in J Allergy Clin Immunol. 2018 Oct;142(4):1374]","volume":"141","author":"Dispenza","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib64","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.1056","article-title":"Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton's tyrosine kinase inhibitor","volume":"103","author":"Herman","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.iac.2020.06.002_bib65","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton's tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.iac.2019.09.007","article-title":"Novel therapies for treatment of food allergy","volume":"40","author":"Albuhairi","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"13","key":"10.1016\/j.iac.2020.06.002_bib68","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2020.06.002_bib69","article-title":"Targeted anti-IL-5 therapies and future therapeutics for hypereosinophilic syndrome and rare eosinophilic conditions","author":"Harish","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"25","key":"10.1016\/j.iac.2020.06.002_bib70","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.iac.2020.06.002_bib71","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/13543784.2019.1672657","article-title":"Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-14-93","article-title":"A\u00a0randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma","volume":"14","author":"Oh","year":"2013","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib73","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.iac.2020.06.002_bib74","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.iac.2020.06.002_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2020.06.002_bib76","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.iac.2020.06.002_bib77","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.iac.2020.06.002_bib78","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:05Z","timestamp":1760179445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856120300370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0889856120300370"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.002","relation":{},"ISSN":["0889-8561"],"issn-type":[{"type":"print","value":"0889-8561"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for the Treatment of Food Allergies","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}